

An Open-Label, Multicentre, Observational, Post-Marketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients

Eun-Yeong Cho, M.D.^{1*}, Jung-Eun Cho, R.N., B.S.N.¹, Eun-Bin Lee, B.S.¹, Seung Soo Yoo, M.D.² and Jung Hyun Chang, M.D.³

¹GSK Korea, Seoul, ²Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, ³Division of Pulmonary and Critical Care Medicine, Ewha Womans University College of Medicine, Seoul, Republic of Korea

Abstract

Background: Umeclidinium/vilanterol (UMEC/VI; ANORO ELLIPTA, GSK) is a commonly used dual bronchodilator. This study evaluated the safety and effectiveness of UMEC/VI in Korean patients with chronic obstructive pulmonary disease (COPD) over a 6-year period.

Methods: This was an open-label, multicentre, observational, post-marketing surveillance study. A total of 3,375 patients were enrolled consecutively in 52 hospitals, by 53 physicians, between July 2014 and July 2020. Patients who were administered UMEC/VI (fixed-dose 62.5 µg/25 µg) at least once and were monitored for safety and effectiveness were included in the analysis. Incidence and severity of adverse events (AEs) reported after administering at least one dose of UMEC/VI were monitored, including unexpected adverse events (UAEs) and adverse drug reactions (ADRs). Effectiveness of UMEC/VI after 24 weeks of administration was also assessed using physician's evaluation (effective, ineffective/no change, worsening, indeterminable) and lung function improvement.

Results: Of 3,375 patients, 3,086 were included in the safety assessment group (mean age±standard deviation: 69.76±8.80 years; 85.9% male [n=2,652]; 73.1% aged ≥65 years [n=2,255]). The overall incidence of AEs was 28.8% (n=890), of which 2.2% (n=67) were ADRs. Serious AEs and UAEs were reported in 181 (5.9%) and 665 (21.6%) patients, respectively, and two patients (<0.1%) reported unexpected severe ADR. Of the 903/3,086 patients analysed for effectiveness, most (82.8%, n=748) showed overall disease improvement after UMEC/VI treatment.

Conclusion: This study confirmed UMEC/VI administered to Korean patients according to the prescribing information was well-tolerated and can be considered an effective option for COPD treatment.

Keywords: Vilanterol; GSK573719; Postmarketing; Safety; Pulmonary Disease, Chronic Obstructive

<https://doi.org/10.4046/trd.2022.0055>

ISSN: 1738-3536(Print)/

2005-6184(Online)

Tuberc Respir Dis 2023;86:33-46



Copyright © 2023 The Korean Academy of Tuberculosis and Respiratory Diseases

Address for correspondence

Eun-Yeong Cho, M.D.

GSK Korea, 92 Hangang-daero, Yongsan-gu, Seoul 04094, Republic of Korea

Phone 82-2-709-4114

Fax 82-2-796-4710

E-mail triangle702@gmail.com

*Current affiliation: Department of Internal Medicine, Sinchon Yonsei Hospital, Seoul, Republic of Korea

Received Apr. 21, 2022

Revised Jul. 13, 2022

Accepted Sep. 25, 2022

Published online Nov. 28, 2022



© It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>).

Introduction

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. This limitation is primarily due to small airway disease and parenchymal destruction associated with an abnormal inflammatory response of the lungs, mainly caused by cigarette smoking¹. COPD is a major cause of ill-health, characterized by chronic and progressive breathlessness (dyspnea), cough, and sputum production², and is one of the top three causes of death worldwide²⁻⁵.

Bronchodilator therapy can ameliorate COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance^{2,6}. Umeclidinium/vilanterol (UMEC/VI; ANORO ELLIPTA, GSK, Seoul, Korea) is a combination inhaler with a long-acting muscarinic antagonist (LAMA) plus a long-acting beta-2-agonist (LABA), licensed for COPD. Administered as a dry powder via oral inhalation⁷, UMEC/VI has proven effective and safe for treating COPD and is approved in >100 countries, demonstrating superior lung function improvement over other LAMA/LABA fixed-dose combinations^{8,9}. However, safety and efficacy data for UMEC/VI in Korean COPD patients are currently lacking.

Korean regulations mandate that new drugs should be re-examined and verified for adverse events (AEs) that did not appear during the approval process for 6 years after the initial approval date, and their safety and efficacy should be re-evaluated at 6, 12, 18, 24, 48, 60, and 72 months¹⁰. UMEC/VI was approved in Korea in 2014. In this study, we aimed to evaluate the safety and effectiveness of UMEC/VI in Korean patients using real-world data, according to post-marketing surveillance (PMS) regulations¹⁰.

Materials and Methods

1. Study design

To demonstrate the safety of UMEC/VI (fixed-dose 62.5 µg/25 µg once daily) 6 years after its approval in Korea, this open-label, multicentre, observational, PMS study was conducted from July 10, 2014 to July 9, 2020, per re-examination regulations from the Korean Ministry of Food and Drug Safety¹⁰.

Physicians conducted patient selection and enrolment processes. Data were collected by physicians from electronic clinical report forms (eCRFs) of patients consecutively diagnosed with COPD from Pulmonary or Pulmonary/Allergy Departments of 52 South Korean general hospitals. The follow-up period was 24 weeks

after initial dose.

This study was conducted in accordance with the guidelines for Good Pharmaco-epidemiology Practices, and the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of each study center including Kyungpook National University Hospital (IRB approval number: KNUMC PMS2015-027).

2. Patients

Eligible participants were those who received a COPD diagnosis during an outpatient visit, with a post-salbutamol forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) ratio <0.7, were ≥19 years of age, received UMEC/VI per domestically approved indications (fixed-dose 62.5 µg/25 µg once daily), and provided informed consent. Patients with asthma, acutely deteriorating COPD, hypersensitivity to UMEC/VI or its components, a severe milk protein allergy, galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption were excluded. There were no restrictions on concomitant drug usage.

3. Study endpoints

Safety endpoints were evaluated in patients who received ≥1 dose of UMEC/VI. Outcomes were based on the incidence of AEs, serious AEs (SAEs), adverse drug reactions (ADRs), and unexpected adverse events (UAEs). All AEs occurring in patients who completed the investigation were included in the safety analysis, irrespective of causality. Classification of AEs was based on the representative terms in Medical Dictionary for Regulatory Activities-Korea 22.1 (MedDRA-K 22.1).

AEs were stratified by gender, age, body mass index (BMI), disease duration, COPD exacerbation of at least moderate severity within ≤12 months, smoking status, medical history, total treatment duration, prior medication related to COPD, concomitant medication related to COPD, and concomitant medication not related to COPD, and by special population, such as elderly patients (≥65 years of age) and patients with renal/hepatic impairment (defined per MedDRA-K 22.1 terms). The total treatment period was defined as the period from the administration start date to the administration end date. If administration of the study drug was still being continued at the investigation end date, “administration end date” was replaced by “follow-up end date” in the analysis.

Effectiveness of UMEC/VI after 24 weeks of prescription initiation was assessed via physician’s evaluation of lung function improvement based on changes in

post-bronchodilation (BD) FEV₁ value according to the 2020 Global Initiative for Chronic Obstructive Lung Disease guidelines¹¹. Individual physicians' global assessments, rated 'effective,' 'no change,' 'worsening,' or 'indeterminable' according to local regulations were recorded, with 'indeterminable' cases excluded from further analysis. Lung function assessment was based on FEV₁ change/mL 24 weeks after UMEC/VI prescription. Additional endpoints were change of BD FEV₁% and improvement in the number and severity of exacerbations.

4. Statistical analyses

Statistical analyses were performed using SAS version software (SAS Institute Inc., Cary, NC, USA), with the crude number and rate of AE and ADR, described using mean and standard deviation (SD). For safety and effectiveness analyses, the percentage of patients reporting AEs were analysed using chi-square test or Fisher's exact test, stratified by factors for subgroup analysis (95% confidence intervals and significance threshold of $p < 0.05$) to identify variables independently affecting the incidence proportion among the special study group.

Multiple logistic regression analyses were performed using nine factors as independent variables (disease duration, COPD exacerbation of at least moderate severity, smoking status, medical history, total treatment duration, prior medication related to COPD, concomitant medication related to COPD, concomitant medication not related to COPD, and elderly population), and AE occurrence as a dependent variable. Continuous

variables were used as independent variables for elderly population, disease duration, and total treatment duration.

5. Data availability

Information on GSK's data sharing commitments and requesting access to anonymized individual participant data and associated documents can be found at www.clinicalstudydatarequest.com.

Results

1. Patient demographics

A total of 3,375 patients were identified for inclusion via retrieval of eCRFs in 52 hospitals, by 53 physicians; of these, 289 patients were excluded due to protocol violation. Thus, 3,086 patients were included in the safety analysis. Among those, 903 patients were included in the effectiveness analysis set (Figure 1).

Of 3,086 patients, 85.9% were male and 73.1% were aged ≥ 65 years. Mean age was 69.8 years and mean duration of disease was 2.5 years. Ex-smokers comprised 52.6% of the population, current smokers 26.4%, and never smokers 21.0%. Overall, 9.0% of patients ($n=279$) experienced moderate or severe COPD exacerbation at least once within ≤ 12 months (Table 1) and 40.8% patients used COPD treatment prior to enrolment. Regarding prior medications (Table 1), 95.3% patients used a long-acting bronchodilator with or without an inhaled corticosteroid (ICS): ICS/LABA, $n=450$; LABA, $n=200$; LAMA, $n=776$; other LAMA/LABA, $n=154$

Figure 1. Study flow diagram. BD: bronchodilator; FEV₁: forced expiratory volume in 1 second.




Table 1. Patient baseline characteristics and demographics (n=3,086)

Characteristic	Value
Male sex	2,652 (85.9)
Age, yr	
Mean age±SD	69.8±8.8
≥65	2,255 (73.1)
BMI, kg/m ² *	3,067 (100.0)
Underweight (<18.5)	313 (10.2)
Normal (18.5 to 23.0)	1,290 (42.1)
Overweight (23.0 to <25.0)	657 (21.4)
Obese (≥25.0)	807 (26.3)
Mean BMI±SD	22.9±3.5
Smoking history	3,086 (100.0)
Current smoker	814 (26.4)
Ex-smoker	1,623 (52.6)
Never smoker	649 (21.0)
COPD exacerbation history (moderate/severe) ≤12 months	3,086 (100.0)
0	2,807 (91.0)
1	220 (7.1)
2	44 (1.4)
≥3	15 (0.5)
COPD treatment prior to UMEC/VI treatment	3,086 (100.0)
Yes	1,258 (40.8)
Classification of prior medication related to COPD [†]	1,258 (100.0)
Long-acting bronchodilator with or without ICS	1,199 (95.3)
ICS/LABA	450 (35.8)
LABA	200 (15.9)
LAMA	776 (61.7)
Other LAMA/LABA (except UMEC/VI)	154 (12.2)
PDE4 inhibitor or oral steroid or methylxanthine	43 (3.4)
Other	56 (4.5)

Values are presented as number (%) unless otherwise indicated.

*Unknown: weight for 17 patients, height for 15 patients. [†]The number of subjects (%) for the classification of prior medication related to COPD are calculated based on the subjects whose prior medication related to COPD is 'Yes.'

SD: standard deviation; BMI: body mass index; COPD: chronic obstructive pulmonary disease; UMEC/VI: umeclidinium/vilanterol; ICS: inhaled corticosteroid; LABA: long-acting beta-2-agonist; LAMA: long-acting muscarinic antagonist; PDE4: phosphodiesterase 4.

(except UMEC/VI). LAMA was the most frequently used treatment prior to using UMEC/VI (Table 1). In total, 80.4% of patients reported any medical history, except COPD (Table 2). Cardiovascular disease (CVD) accounted for the largest proportion of reported medical history (48.9%), followed by diabetes mellitus (19.0%) and lung cancer (9.2%) (Table 2). Of the 3,086 patients in the safety analysis set, 58.5% had concomitant medication related to COPD (Table 3). In terms of classification of medication, short-acting beta-2-agonists (SABA)

accounted for the largest proportion (15.9%), followed by ICS/LABA (6.8%) and ICS alone (4.9%) (Table 3). Overall, 67.4% of patients had concomitant medication not related to COPD (Table 4). The highest proportion of these medications belonged to the gastrointestinal and hepatobiliary system class (52.2%), followed by the cardiovascular and hematopoietic system (42.4%) and the respiratory system (41.3%) (Table 4).

Patients were treated with UMEC/VI (74.2 μg/40 μg) for a mean 187 days. Overall, 898 patients successfully

Table 2. Patient medical history

Variable	No. of patient (%)
Medical history	
Yes	2,480 (80.4)
No	606 (19.6)
Diagnostic classification of medical history* (overlapped)	
Liver disease	119 (4.8)
Kidney disease	135 (5.4)
Cardiovascular disease	1,212 (48.9)
Diabetes mellitus	471 (19.0)
Lung cancer	228 (9.2)
Other	2,086 (84.1)
Details of medical history* (overlapped)	
Vascular disorders	999 (40.3)
Respiratory, thoracic and mediastinal disorders	703 (28.4)
Metabolism and nutrition disorders	690 (27.8)
Infections and infestations	643 (25.9)
Gastrointestinal disorders	594 (24.0)
Neoplasms benign, malignant and unspecified	509 (20.5)
Cardiac disorders	526 (21.2)
Reproductive system and breast disorders	322 (13.0)
Nervous system disorders	266 (10.7)
Musculoskeletal and connective tissue disorders	215 (8.7)
Renal and urinary disorders	186 (7.5)
Psychiatric disorders	165 (6.7)
Hepatobiliary disorders	121 (4.9)
Eye disorders	87 (3.5)
Injury, poisoning and procedural complications	85 (3.4)
Skin and subcutaneous tissue disorders	72 (2.9)
Endocrine disorders	69 (2.8)
Blood and lymphatic system disorders	55 (2.2)
General disorders and administration site conditions	37 (1.5)
Congenital, familial and genetic disorders	41 (1.7)
Ear and labyrinth disorders	29 (1.2)
Immune system disorders	17 (0.7)
Investigations	7 (0.3)
Social circumstances	3 (0.1)
Surgical and medical procedures	3 (0.1)

*The percentage patients for diagnostic classification and details of medical history are calculated based on the patients whose medical history is "Yes."

obtained a spirometry test; baseline mean±SD FEV₁ and FVC were 1.55±0.55 and 2.95±0.84 L, respectively, and mean FEV₁% predicted was 58.0%±16.3%.

2. Safety analysis

1) Incidence of AEs and ADRs

Overall, AEs were reported by 28.8% (n=890) of patients (Table 5). Respiratory, thoracic, and mediastinal

Table 3. Concomitant medication related to COPD

Variable	No. of patient (%)
Concomitant medication related to COPD	
Yes	1,805 (58.5)
No	1,281 (41.5)
Classification of concomitant medication* (overlapped)	
SABA	287 (15.9)
SAMA	33 (1.8)
ICS	88 (4.9)
ICS/LABA	122 (6.8)
Oral steroid	87 (4.8)
Other	1,610 (89.2)
Details of concomitant medication by class	
Respiratory system	1,781 (98.7)
Anti-asthmatic and COPD preparations	1,529 (84.7)
Cough and cold preparations	849 (47.0)
Nasal decongestants	2 (0.1)
Hormones	98 (5.4)
Corticosteroid hormones	98 (5.4)
Allergy and immune system	88 (4.9)
Antihistamines and anti-allergics	60 (3.3)
Vaccines, antisera and immunologicals	28 (1.6)
Anti-infectives (systemic)	59 (3.3)
Quinolones	42 (2.3)
Cephalosporins	15 (0.8)
Macrolides	13 (0.7)
Penicillins	3 (0.2)
Antifungals	2 (0.1)
Other beta-lactams	1 (0.1)
Other antibiotics	1 (0.1)
Aminoglycosides	1 (0.1)
Central nervous system	8 (0.4)
Analgesics (non-opioid) and antipyretics	5 (0.3)
Analgesics (opioid)	3 (0.2)
Musculo-skeletal system	2 (0.1)
Anti-inflammatory enzymes	2 (0.1)
Nutrition	1 (0.1)
Parental nutritional products	1 (0.1)

*The percentage of patients for the classification of concomitant medication related to COPD are calculated based on the patients whose concomitant medication related to COPD is "Yes."
 COPD: chronic obstructive pulmonary disease; SABA: short-acting beta-2-agonist; SAMA: short-acting muscarinic antagonist; ICS: inhaled corticosteroid; LABA: long-acting beta-2-agonist.

Table 4. Concomitant medication not related to COPD

Variable	No. of patient (%)
Concomitant medication not related to COPD	
Yes	2,079 (67.4)
No	1,007 (32.6)
Details of concomitant medications by class* (overlapped)	
Gastrointestinal and hepatobiliary system	1,086 (52.2)
Antacids, anti-reflux and anti-ulcerants	965 (46.4)
GIT regulators, anti-flatulents and anti-inflammatories	218 (10.5)
Laxatives and purgatives	104 (5.0)
Cardiovascular and hematopoietic system	881 (42.4)
Anti-coagulants, anti-platelets and fibrinolytics	453 (21.8)
Dyslipidaemic agents	351 (16.9)
Calcium antagonists	252 (12.1)
Angiotensin II antagonists	219 (10.5)
Beta-blockers	215 (10.3)
Diuretics	191 (9.2)
Other anti-hypertensives	136 (6.5)
Anti-anginal drugs	135 (6.5)
Respiratory system	858 (41.3)
Cough and cold preparations	722 (34.7)
Anti-asthmatic and COPD preparations	208 (10.0)
Central nervous system	481 (23.1)
Analgesics (non-opioid) and antipyretics	173 (8.3)
Non-steroidal anti-inflammatory drugs	121 (5.8)
Anti-infectives (systemic)	449 (21.6)
Cephalosporins	191 (9.2)
Quinolones	158 (7.6)
Macrolides	122 (5.9)
Allergy and immune system	414 (19.9)
Antihistamines and anti-allergics	352 (16.9)
Endocrine and metabolic system	245 (11.8)
Anti-diabetic agents	203 (9.8)
Genito-urinary system	228 (11.0)
Drugs for bladder and prostate disorders	223 (10.7)
Hormones	134 (6.5)
Corticosteroid hormones	133 (6.4)

*The percentage of patients for the classification and details of concomitant medication not related to COPD are calculated based on the subjects whose concomitant medication not related to COPD is "Yes."
COPD: chronic obstructive pulmonary disease; GIT: gastrointestinal tract.

disorders were the most reported AEs by system organ class (12.5%, n=385), followed by infections and infestations (6.7%, n=207), and gastrointestinal disorders (4.7%, n=146). In the analysis by preferred term, the

most common AEs were dyspnea (3.3%, n=102), cough (2.9%, n=90), and upper respiratory tract infection (2.9%, n=89) (Table 5). Out of 890 patients with AEs, 2.2% (n=67) reported ADRs (Table 5), the most com-

Table 5. Summary of adverse events, adverse drug reactions, and serious adverse events (n=3,086)

Variable	No. of patient with AE (%)	No. of event
Total AEs	890 (28.8)	1,463
Most frequent AEs*		
Dyspnea	102 (3.3)	106
Cough	90 (2.9)	90
COPD	77 (2.5)	87
Productive cough	58 (1.9)	62
Upper respiratory tract infection	89 (2.9)	98
Pneumonia	53 (1.7)	55
ADRs	67 (2.2)	74
Most frequent ADRs*		
Cough	19 (0.6)	19
Dry mouth	10 (0.3)	10
Nausea	6 (0.2)	6
SAEs	181 (5.9)	212
Most frequent SAEs*		
COPD	36 (1.2)	39
Pneumonia	35 (1.1)	36
Serious ADRs [†]	3 (0.1)	3
COPD (aggravation)	1 (0.03)	1
Pneumonia	1 (0.03)	1
Glaucoma	1 (0.03)	1
UAEs	665 (21.6)	1,036
Unexpected ADRs	25 (0.8)	27
Unexpected SAEs	161 (5.2)	192
Unexpected serious ADRs	2 (0.06)	2

*Listed by preferred term (MedDRA-K 22.1) are the events occurring in $\geq 1\%$ of patients or, for categories with fewer than three event frequencies $\geq 1\%$, the three most frequent events. [†]Serious adverse drug reactions represent the adverse drug reactions that correspond to an event which results in or prolongs hospitalization.

AE: adverse event; COPD: chronic obstructive pulmonary disease; ADR: adverse drug reaction; SAE: serious adverse event; UAE: unexpected adverse event.

mon being cough (0.6%, n=19), dry mouth (0.3%, n=10), and nausea (0.2%, n=6).

2) Incidence of SAEs and serious ADRs

SAEs were reported by 5.9% (n=181) of patients (Table 5); the most commonly reported SAEs were COPD, pneumonia, and dyspnea (Table 5). Serious ADRs were reported by three patients (0.1%; one aggravation of COPD, one pneumonia, one glaucoma) (Table 5). In the patient with COPD and the patient with pneumonia, symptoms resolved after appropriate treatment and UMEC/VI treatment was maintained; for the patient with glaucoma, UMEC/VI treatment was discontinued, and appropriate treatment given.

3) UAEs, severe UAEs with unexpected ADRs

UAEs were seen in 21.6% (n=665) of patients and unexpected ADRs in 0.8% (n=25) of patients (Table 5), with nausea being the most commonly reported (0.2%, n=6). Unexpected SAEs were reported by 5.2% (n=161) patients and two unexpected serious ADRs (0.01%) were reported (one COPD, one pneumonia).

4) Relevant factors with safety outcomes

Among 1,463 reported AEs, 1,071 were mild, 336 moderate, and 56 severe. A causal relationship with UMEC/VI was deemed 'unlikely' in 1,389 cases, 'likely' in 52 cases, 'very likely' in 18 cases, 'certain' in three cases, and 'unevaluable' in one case. Class-related AEs

associated with high-dose LABA were rare (tremors [0.1%], blood pressure changes [0.1%], tachycardia, arrhythmia [$<0.1\%$]), with no reporting of tachycardia or palpitations. Drug-related AEs associated with LAMAs, e.g., constipation ($<1\%$), dryness of mouth ($<1\%$), and urinary retention ($<1\%$), occurred at low frequencies. There were 317 unresolved and 88 unknown cases, 16 deaths (deemed unlikely to be product-related by the investigator), and four sequelae cases. Treatment con-

tinued in 1,303 cases, while treatment was suspended permanently in 143 cases and temporarily in 12 cases; action taken was unknown in five cases, and appropriate versus inappropriate treatment was given in 939 versus 524 cases, respectively.

Differences in AE incidence were statistically significant for nine factors: disease duration, COPD exacerbation of at least moderate severity, medical history, total treatment duration, prior medication related to COPD,

Table 6. Univariate analysis for factors related to AE incidence: safety analysis set

Variable	No. of patient with AE (%)	No. of event	p-value
Disease duration, yr			
<1	399 (25.2)	620	<0.0001
≥ 1	483 (32.9)	832	
COPD exacerbation (of at least moderate severity)			
Yes	113 (40.5)	203	<0.0001
No	777 (27.7)	1,260	
Medical history			
Yes	763 (30.8)	1,298	<0.0001
No	127 (21.0)	165	
Total treatment duration			
<3 months	159 (22.1)	229	<0.0001
3 months to <6 months	272 (29.3)	433	
6 months to <1 year	374 (33.2)	672	
≥ 1 year	73 (29.2)	113	
Prior medication related to COPD			
Yes	423 (33.6)	726	<0.0001
No	467 (25.6)	737	
Concomitant medication related to COPD			
Yes	593 (32.9)	1,028	<0.0001
No	297 (23.2)	435	
Concomitant medication not related to COPD			
Yes	739 (35.6)	1,282	<0.0001
No	151 (15.0)	181	
Smoking status			
Current smoker	202 (24.8)	329	0.0102
Ex-smoker	485 (29.9)	816	
Non-smoker	203 (31.3)	318	
Elderly population			
<65 years of age	213 (25.6)	342	0.0169
≥ 65 years of age	677 (30.0)	1,121	

Shown are the factors that were statistically significant ($p < 0.05$) by univariate analysis of the association of each factor with AE incidence using the chi-square test.

AE: adverse event; COPD: chronic obstructive pulmonary disease.

concomitant medication related to COPD, concomitant medication not related to COPD (all $p < 0.0001$), smoking status ($p = 0.0102$), and elderly population ($p = 0.0169$) (Table 6).

Logistic regression was performed using the nine factors with statistically significant difference in AE incidence in the analysis by background factor as independent variables and AE occurrence as a dependent variable. As elderly population, disease period and total administration period were classified based on age, administration period and total administration period, respectively, continuous variables were used as independent variables in the analysis. As a result, it was found that the factors significantly affecting AE occurrence were COPD exacerbation at least moderate severity within recent 1 year ($p = 0.0213$), smoking status ($p = 0.0178$), total administration period ($p = 0.0445$), prior medication related to COPD ($p = 0.0238$), concomitant medication related to COPD ($p = 0.0166$), and concomitant medication not related to COPD ($p < 0.0001$) (Table 7).

No change in odds ratio was observed for increased treatment duration during the total treatment administration period. Patients who received the study drug for 6 months to <1 year reported the highest incidence of AEs at 33.2% (374/1127), followed by the 3 to <6 months group at 29.3% (272/929), the ≥ 1 year group at 29.2% (73/250), and the <3 months group at 22.1% (159/720) ($p < 0.0001$ in univariate analysis) (Table 6). The odds ratio was 1.37 times higher in patients with COPD exacerbation of at least moderate severity within ≤ 12 months compared to those without, 1.23 times higher in patients with COPD-related prior medication compared to those without, 1.25 times higher in patients with COPD-related concomitant medication compared to those without, 2.81 times higher in patients with concomitant medication not related to COPD compared to those without, and 0.74 times lower in ex-smokers compared to non-smokers (Table 7).

3. Effectiveness analysis

Overall, 903 patients from the safety analysis set were

Table 7. Multivariate logistic regression for adverse events: safety analysis set

Variable	Parameter estimate	SE	Wald chi-square	p-value	OR	95% CI
Age, yr	0.00	0.00	0.04	0.8474	1.00	0.99–1.01
Disease duration, yr	0.00	0.01	0.06	0.8010	1.00	0.98–1.03
COPD exacerbation history (at least moderate severity) within ≤ 12 months						
Yes vs. no	0.32	0.14	5.30	0.0213	1.37	1.05–1.80
Smoking history						
Current smoker vs. non-smoker	-0.08	0.11	0.59	0.4406	0.92	0.75–1.14
Ex-smoker vs. non-smoker	-0.30	0.12	5.61	0.0178	0.74	0.58–0.95
Medical history*						
Yes vs. no	-0.01	0.12	0.00	0.9581	0.99	0.78–1.27
Total treatment duration within investigation period, day	0.00	0.00	4.04	0.0445	1.00	1.00–1.00
Prior medication related to COPD						
Yes vs. no	0.21	0.09	5.11	0.0238	1.23	1.03–1.47
Concomitant medication related to COPD						
Yes vs. no	0.22	0.09	5.74	0.0166	1.25	1.04–1.49
Concomitant medication not related to COPD						
Yes vs. no	1.03	0.11	82.23	<0.0001	2.81	2.25–3.51

Dependent variable: reference category 'No.' Independent variable: factors with the $p < 0.05$ in the special populations and demographic and baseline data. In the analysis, age was used for elderly population and continuous data were used for disease duration and total treatment duration.

*Includes previous diagnosis of cardiovascular disease, osteoporosis, diabetes, and lung cancer.

SE: standard error; OR: odds ratio; CI: confidence interval; COPD: chronic obstructive pulmonary disease.

included in the effectiveness analysis set (Figure 1). In total, 478 (52.9%) patients from the effectiveness analysis had received prior medication related to COPD, including long-acting bronchodilators with or without ICS. In addition, 548 (60.7%) of patients in the effectiveness analysis set reported concomitant medication related to COPD, including SABA, short-acting muscarinic antagonists (SAMA) and ICS with LABA. FEV₁ values were collected before and after study drug administration in 898/903 (99.4%) patients in the effectiveness analysis. Mean FEV₁±SD was 1.55±0.55 L before administration and 1.68±0.58 L after administration; mean change in FEV₁ was 0.13±0.25 L (p<0.0001) (Figure 2A). Mean FVC was 2.95±0.84 L before administration and 3.06±0.85 L after administration; mean change in FVC was 0.12±0.38 L (p<0.0001) (Figure 2A). The mean FEV₁/FVC ratio was 52.9%±11.8% before administration and 55.1%±12.5% after administration; mean change in FEV₁/FVC ratio was 2.3%±6.1% (p<0.0001) (Figure 2B). Investigator-assessed effectiveness revealed 82.8% of patients improved (n=748), 15.7% were unchanged (n=142), and 1.4% had aggravated disease (n=13) (Figure 2C).

Discussion


Patients with COPD in Korea display several unique features, including a high prevalence of tuberculosis, biomass smoke exposure and lower BMIs compared with Western populations^{12,13}. AEs in COPD are known to increase in patients with low BMI or underlying dis-

eases¹⁴. Therefore, it is important to verify the safety of UMEC/VI in Korean patients with multiple risk factors for COPD. This study on the safety of UMEC/VI in a high-risk population is important since there have been no safety studies of dual bronchodilators in Korea to date.

The population in this study was of a similar mean age, albeit different smoking history, to the general COPD population across South Korea¹⁵. A 2014 database review found the mean age of COPD patients across Korea was 69.3 years¹⁶, compared with 69.8 years in our study. Furthermore, 2008 National Health and Nutrition Survey data established a sex disparity for COPD prevalence in Korea (men 19.4%; women 7.9%)¹⁷. In this study, 83.7% of patients were male and 80% of patients had underlying diseases (48.9% CVD, 19% diabetes, and 9.2% lung cancer), in line with other countries¹⁸⁻²⁰.

The incidence of AEs was 28.8%, and SAEs was 5.9%, lower than those reported in a previous phase 3 clinical trial (DB 2113373)²¹, which reported on-treatment AEs in 51% (212/413) patients, and on-treatment SAEs in 5% of patients (21/413)²¹. The variation may be due to the different study designs and patient demographics between the studies. DB 2113373 was a 4-arm study with 24 weeks observation and more detailed inclusion/exclusion criteria than our study (e.g., symptomatic patients with a Modified Medical Research Council score >2 points were eligible for inclusion in DB 2113373; however, non-symptomatic patients were eligible for inclusion in our study because there were

Figure 2. (A) Forced expiratory volume in 1 second (FEV₁) and forced vital capacity (FVC) measurements of patients before/after administration of study drug and mean change in FEV₁. (B) Mean FEV₁/FVC ratio measurements of patients before/after administration of study drug and mean change in FEV₁/FVC ratio. (C) Investigator-assessed effectiveness. *p<0.0001.



no inclusion criteria related to COPD symptoms).

Previously reported class effect AEs associated with high-dose LABA include tremors, blood pressure changes, tachycardia, arrhythmia, and palpitations^{22,23}. These events were rare or not observed as were drug-related AEs associated with LAMAs; an unexpected small increase in cardiovascular events in COPD patients with ipratropium bromide, a SAMA, has been previously reported²⁴. As both LAMA and LABA have possible class-related cardiac disorder effects, incidence of a rare drug-related AEs (palpitation, 0.1%) can be indicative of drug tolerability.

In this study, nine factors significantly affected the occurrence of AEs in univariate analyses: disease duration, COPD exacerbation of at least moderate severity within ≤ 12 months, smoking status, medical history, total treatment duration, prior COPD-related medication, COPD-related concomitant medication, concomitant medication not related to COPD, and older age. In a previous study, COPD exacerbation compromised health status, accelerated disease progression, and caused serious symptoms; function was irreversible to baseline levels in some patients and cardiovascular SAEs occurred more frequently²⁵. This is in line with our findings that COPD exacerbation causes more frequent AEs.

In our study, never smokers were at a higher risk of developing an AE than former smokers. As smoking is reported as the greatest risk factor for COPD, and considering the COPD characteristics of irreversible airflow limitation are due to long-term exposure to risk factors²⁶, elucidation of the clinical meaning of these findings is difficult. AE incidence might have been affected by patient factors other than smoking history (e.g., COPD status at the time of surveillance participation, indirect smoke inhalation, etc.).

An association between AEs and prior medication related to COPD and concomitant medication both related and unrelated to COPD was observed in the present study. However, it is important to note that these medications may have caused the AE. As a result, it is difficult to consider the importance of these factors in a clinical setting despite their statistical significance. Patient medical history is another factor that significantly affected the occurrence of AEs in our study. There is evidence that CVD can affect COPD patients and is associated with various unfavorable outcomes, including reduced quality of life, increased hospitalization risk, and increased risk for all-cause and CVD mortality²⁷. Almost half the patients in our study with a medical history, other than COPD, reported CVD. Therefore, this may account for the association between medical history

and occurrence of AEs observed in our study.

Increased risk of cardiovascular events, leading to hospitalization and emergency department visits, has previously been reported in new users or bronchodilators²⁸. One study found that cardiovascular events in new users were highest in the first 3 weeks after the medication was prescribed²⁸. The findings from our study showed that treatment duration significantly affected the incidence of AEs. This association may have been due to an increased incidence of AEs in new users in our study; however, this was not formally assessed.

Patient age was another factor identified in our study, with older age significantly affecting the occurrence of AEs. A long-term safety study of tiotropium/olodaterol in patients with COPD reported that the proportion of patients that reported AEs was higher in older patients²⁹. The increased risk of AEs in older patients with COPD may be due to an increase in comorbidities and concomitant medications in this patient group^{29,30}. This is consistent with our findings that showed that older age, concomitant medication and medical history all significantly affected the occurrence of AEs.

In this study, UMEC/VI was shown to be effective in 82.8% of patients, with a mean \pm SD change in FEV₁ of 0.13 \pm 0.25 L. This improvement was not as marked as data from a global phase 3 efficacy study of UMEC/VI, DB 2113373²¹; however, baseline lung function was higher in our study which may account for the differences in lung function improvements observed between the two studies.

In terms of limitations, our study was an open-label study without a control group, therefore it was only possible to measure the improvement of lung function before and after UMEC/VI use. In addition, since this is an observational study, AEs were collected by patients' self-reported data. In this open-label, observational, multicentre, PMS study, the licensed dose of UMEC/VI trifenate (62.5 μ g/25 μ g) was well-tolerated over 24 weeks of treatment in patients with COPD in Korea. AEs thought to be a 'class effect' of LAMA/LABA treatment were either not or rarely observed during the course of this 6-year post-marketing period. Five factors significantly affected the odds of an AE in multivariate analyses (COPD exacerbation severity, COPD-related prior and concomitant medications, non-COPD-related concomitant medication, and smoking). Of the 903/3,086 patients analysed for effectiveness, the majority (82.8%) showed overall disease improvement after UMEC/VI treatment. The results of this study further support the safety and effectiveness of UMEC/VI for the treatment of COPD.

Authors' Contributions

Conceptualization: Cho JE. Formal analysis: Cho EY, Cho JE, Lee EB. Investigation: Yoo SS, Chang JH. Writing - original draft preparation: Cho EY. Writing - review and editing: Cho EY, Cho JE, Lee EB, Yoo SS, Chang JH. Approval of final manuscript: all authors.

Conflicts of Interest

Eun-Yeong Cho was an employee and shareholder, Jung-Eun Cho, and Eun-Bin Lee are employees of GSK. Seung Soo Yoo and Jung Hyun Chang disclosed no conflict of interests.

Acknowledgments

Editorial support for the development of this manuscript, under the direction of the authors, was provided by Rebecca Benatan, BSc, and Fiona Scott, Ph.D., of Ashfield MedComms, Macclesfield and Glasgow, UK, an Ashfield Health Company, and was funded by GSK.

Funding

This study (204511) was funded by GSK. Trademarks are owned by or licensed to their respective owners (GSK [ANORO ELLIPTA]).

References

1. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932-46.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). Fontana: GOLD; 2021. p. 164.
3. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. *Eur Respir J* 2006; 27:188-207.
4. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J* 2006; 27:397-412.
5. Halpin DM, Celli BR, Criner GJ, Frith P, Lopez Varela MV, Salvi S, et al. The GOLD summit on chronic obstructive pulmonary disease in low- and middle-income countries. *Int J Tuberc Lung Dis* 2019;23:1131-41.
6. Miravittles M, D'Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. *Respir Res* 2016;17:112.
7. GlaxoSmithKline. UMEC/VI Korean Prescribing Information [Internet]. Anyang: Korea Institute of Drug Safety & Risk Management; 2014 [cited 2022 Dec 5]. Available from: <https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=201403055>.
8. Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. *Adv Ther* 2017;34:2518-33.
9. Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, et al. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol. *Int J Chron Obstruct Pulmon Dis* 2019;14:2047-60.
10. Ministry of Food and Drug Safety. Safety control after releasing medicinal products etc.: guideline on re-examination affairs of new drugs etc. (A guide for civil petitioner). Cheongju: Ministry of Food and Drug Safety; 2019.
11. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Fontana: GOLD; 2020.
12. Rhee CK, Chau NQ, Yunus F, Matsunaga K, Perng DW; on behalf the COPD Assembly of the APSR. Management of COPD in Asia: a position statement of the Asian Pacific Society of Respiriology. *Respirology* 2019;24:1018-25.
13. Lim SY, Choi WI, Jeon K, Guallar E, Koh Y, Lim CM, et al. Body mass index and mortality in Korean intensive care units: a prospective multicenter cohort study. *PLoS One* 2014;9:e90039.
14. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010;363:1128-38.
15. Lee JY, Chon GR, Rhee CK, Kim DK, Yoon HK, Lee JH, et al. Characteristics of patients with chronic obstructive pulmonary disease at the first visit to a pulmonary medical center in Korea: The Korea COPD Subgroup Study Team Cohort. *J Korean Med Sci* 2016;31:553-60.
16. Kim C, Yoo KH, Rhee CK, Yoon HK, Kim YS, Lee SW, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. *Int J Tuberc Lung Dis* 2014;18:737-43.
17. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, KIM SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. *Respirology* 2011;16:659-65.
18. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic ob-

- structive pulmonary disease. *Respiration* 2010;80:112-9.
19. Andre S, Conde B, Fragoso E, Boleo-Tome JP, Areias V, Cardoso J, et al. COPD and cardiovascular disease. *Pulmonology* 2019;25:168-76.
 20. Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. *Eur Respir J* 2012;39:1230-40.
 21. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. *Respir Med* 2013;107:1538-46.
 22. Novartis. Indacaterol prescribing information [Internet]. Silver Spring: FDA; 2021 [cited 2022 Dec 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022383s009s010lbl.pdf.
 23. GlaxoSmithKline. Salmeterol prescribing information [Internet]. Brentford: GlaxoSmithKline; 2020 [cited 2022 Dec 5]. Available from: http://us.gsk.com/products/assets/us_serevent_diskus.pdf.
 24. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. *Am J Respir Crit Care Med* 2002;166:333-9.
 25. Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UP-LIFT trial. *Lung* 2011;189:261-8.
 26. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. *BMC Pulm Med* 2011;11:36.
 27. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? *Ther Adv Respir Dis* 2018;12:1753465817750524.
 28. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. *JAMA Intern Med* 2013;173:1175-85.
 29. Ferguson GT, Maltais F, Karpel J, Bothner U, Kloer I, Trampisch M, et al. Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO studies. *NPJ Prim Care Respir Med* 2020;30:53.
 30. Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD: its impact on health service utilisation and quality of life, a community study. *Age Ageing* 2006;35:33-7.